The Senate should stand by a House bill that would curb "pay for delay" deals between brand-name and generic-drug companies in order to save consumers billions of dollars and reduce the federal budget deficit, according to this New York Times editorial. House lawmakers passed the bill last week with compromise language that would allow companies to overcome a presumption deeming such agreements illegal.

Related Summaries